Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Tyra Biosciences, Inc.NASDAQ: TYRA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$138K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$138K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$138K or moves back toward the trailing-twelve-month quarterly average of -$34.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$138K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$138K-9.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's LTM Mar 2026 gross profit of -$138K is the 10th highest of the 11 companies compared; the peer median is $8.99M.
  • Its year-over-year change of -9.5% is the 8th highest of 9, against a peer median of +8.1%.
TYRA Competitors Peer median
Gross Profit for TYRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026$159.6M +3936.4%—93.9%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
KURAKura Oncology, Inc.LTM Mar 2026$67.81M +0.0%—94.7%
VSTMVerastem, Inc.LTM Mar 2026$41.53M +315.3%+114.5%83.7%
JANXJanux Therapeutics, Inc.LTM Mar 2026$11.7M +129.7%+0.9%54.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M -73.3%+12.8%22.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$0 ———
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$79K -2.6%——
TYRATyra Biosciences, Inc.LTM Mar 2026-$138K -9.5%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K -5.3%——
Peer median (excluding TYRA) $8.99M+8.1%+6.8%76.8%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development20.64M43.01M62.52M80.08M102.93M
Selling, General & Admin5.65M15.92M17.43M24.1M29.83M
Operating Expenses26.29M58.93M79.95M104.18M132.76M
Depreciation & Amortization140K296K357K519K546K
EBITDA(26.15M)(55.03M)(68.78M)(85.96M)(119.4M)
EBITDA Margin—————
Operating Income(26.29M)(58.93M)(79.95M)(104.18M)(132.76M)
Operating Margin—————
Interest Income13K3.65M10.81M17.7M12.82M
Interest Expense00000
Other Income / Expenses(6K)3.6M10.81M17.7M12.82M
Income Before Tax(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Net Margin—————
EPS (Basic)(0.63)(1.23)(1.62)(1.51)(2.01)
EPS (Diluted)(0.63)(1.23)(1.62)(1.51)(2.01)
Weighted Avg Shares41.44M41.88M42.7M57.22M59.6M
Weighted Avg Shares (Diluted)41.44M41.88M42.7M57.22M59.6M

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.